SWOG clinical trial number
CTSU/C10603
Phase III Randomized Study of Induction Therapy Comprising Daunorubicin Hydrochloride and Cytarabine With or Without Midostaurin Followed by Consolidation Therapy Comprising High-Dose Cytarabine and Midostaurin Followed by Continuation Therapy Comprising Midostaurin Alone in Patients With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
Closed
Phase
Published
Abbreviated Title
Phase III Flt3+ AML Daunorubicin+AraC +/- Midostaurin Induction, AraC/Midostaurin Consolidation, Midostaurin Continuation
Activated
02/01/2009
Closed
10/15/2011
Participants
CTSU
Research committees
Leukemia
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
CTSU/A042001
SWOG Clinical Trial Number
Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
S1925
SWOG Clinical Trial Number
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
62% Accrual
Accrual
62%
Open
Phase
CTSU/AALL1821
SWOG Clinical Trial Number
Research Committee(s)
Leukemia
Activated
12/04/2020
Open